Moderna Total Liab vs Net Working Capital Analysis
MRNA Stock | USD 107.97 1.79 1.69% |
Moderna financial indicator trend analysis is infinitely more than just investigating Moderna recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moderna is a good investment. Please check the relationship between Moderna Total Liab and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
Total Liab vs Net Working Capital
Total Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moderna Total Liab account and Net Working Capital. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Moderna's Total Liab and Net Working Capital is 0.87. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Moderna, assuming nothing else is changed. The correlation between historical values of Moderna's Total Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Moderna are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Liab i.e., Moderna's Total Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.87 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Net Working Capital
Most indicators from Moderna's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moderna current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.At present, Moderna's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 1.2 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.19.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 18M | 200M | 405M | 425.3M | Net Interest Income | 18M | 200M | 363M | 381.2M |
Moderna fundamental ratios Correlations
Click cells to compare fundamentals
Moderna Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Moderna fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.6B | 7.3B | 24.7B | 25.9B | 18.4B | 19.3B | |
Total Current Liabilities | 143.1M | 4.4B | 9.1B | 4.9B | 3.0B | 2.4B | |
Total Stockholder Equity | 1.2B | 2.6B | 14.1B | 19.1B | 13.9B | 14.5B | |
Other Liab | 139.1M | 179.3M | 691M | 808M | 929.2M | 975.7M | |
Net Tangible Assets | 1.2B | 2.6B | 14.1B | 19.1B | 22.0B | 23.1B | |
Retained Earnings | (1.5B) | (2.2B) | 10.0B | 18.3B | 13.6B | 14.3B | |
Accounts Payable | 7.1M | 18.4M | 302M | 487M | 520M | 546M | |
Cash | 235.9M | 2.6B | 6.8B | 3.2B | 2.9B | 1.8B | |
Net Receivables | 16.3M | 1.4B | 3.3B | 1.4B | 1.1B | 886.7M | |
Other Current Assets | 887.9M | (405.6M) | 55M | 1.2B | 88M | 83.6M | |
Total Liab | 414.6M | 4.8B | 10.5B | 6.7B | 4.6B | 3.1B | |
Total Current Assets | 1.3B | 6.3B | 17.6B | 13.4B | 10.3B | 5.8B | |
Common Stock | 33K | 34K | 40K | (857M) | (771.3M) | (732.7M) | |
Other Current Liab | 5.1M | 33.7M | 2.4B | 2.2B | 1.9B | 2.0B | |
Common Stock Shares Outstanding | 330.8M | 381.3M | 431M | 416M | 382M | 346.5M | |
Short Long Term Debt Total | 132.4M | 207.3M | 916M | 1.2B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 287.9M | 387.1M | 1.4B | 2.1B | 2.7B | 2.8B | |
Current Deferred Revenue | 63.3M | 3.9B | 6.3B | 2.0B | 568M | 539.6M | |
Net Debt | (103.5M) | (2.4B) | (5.9B) | (2.0B) | (1.7B) | (1.7B) | |
Non Current Assets Total | 326.4M | 1.0B | 7.1B | 12.4B | 8.1B | 4.1B | |
Non Currrent Assets Other | (121.5M) | 12.9M | 46M | 988M | 523M | 549.2M | |
Other Assets | 12.7M | 742.0M | 7.4B | 1.9B | 2.2B | 1.6B | |
Cash And Short Term Investments | 1.3B | 5.2B | 17.6B | 9.9B | 8.6B | 6.3B | |
Short Term Investments | 867.1M | 2.0B | 3.9B | 6.7B | 5.7B | 3.0B | |
Liabilities And Stockholders Equity | 1.6B | 7.3B | 24.7B | 25.9B | 18.4B | 11.3B | |
Non Current Liabilities Total | 271.5M | 386.6M | 1.4B | 1.8B | 1.6B | 868.0M | |
Capital Surpluse | 2.7B | 4.8B | 4.2B | 1.2B | 1.3B | 2.4B | |
Capital Lease Obligations | 132.4M | 207.3M | 916M | 1.0B | 1.2B | 1.3B | |
Other Stockholder Equity | 2.7B | 4.8B | 4.2B | 1.2B | 371M | 352.5M | |
Long Term Investments | 160.0M | 638.8M | 6.8B | 8.3B | 4.7B | 2.9B | |
Accumulated Other Comprehensive Income | 1.8M | 3.0M | (24M) | (370M) | (123M) | (116.9M) | |
Non Current Liabilities Other | 138K | 386.6M | 1.4B | 135M | 256M | 299.3M | |
Short Term Debt | 67.7M | 469.6M | 211M | 196M | 25M | 23.8M | |
Property Plant Equipment | 287.9M | 387.1M | 1.4B | 2.1B | 2.5B | 2.6B | |
Net Invested Capital | 1.2B | 2.6B | 14.1B | 19.1B | 13.9B | 8.1B | |
Property Plant And Equipment Gross | 287.9M | 387.1M | 1.7B | 2.1B | 3.1B | 3.2B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (12.33) | Revenue Per Share 17.927 | Quarterly Revenue Growth (0.45) | Return On Assets (0.12) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.